drugset / Trial / NCT00313794

Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment

NCT00313794 ↗

Phase 2 Completed 49 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is for patients with metastatic adenocarcinoma arising from the colon or rectum who have received treatment(s) for metastatic disease with subsequent disease progression. Patients who are intolerant to treatment(s) are also included. This is a study for good performance status colorectal cancer patients who have exhausted standard therapy options.

Timeline

Start
2006-05
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tremelimumab Monoclonal antibody 15 mg/kg Intravenous

Indications